Live · updated 3 November 2026

My One View

My whole cancer on one sheet. Every fact says where it came from, it's updated every chemo cycle, and it's all open: take it, use it, tell me what I've missed.

If you only take one thing away, take the One View. It's the whole story on one sheet of A4, and it's always the latest version.

Download my One View (PDF) Full record → On right now →

In a hurry, or standing at a pharmacy counter in another country? fcancerwith.ai/now is the fifteen-second version: what I'm on, what's unsafe to give me, and what to do if I'm unwell. It works with no signal once you've opened it.

Copied. Paste it straight into an email or your notes.

What is One View?

My whole cancer on one sheet

Diagnosis, genetics, every treatment and how it went, latest bloods and scans, everything I take, and the open questions. Each fact says where it came from. It's updated every chemo cycle, so a new doctor can get up to speed in a minute.

I think every patient should have one. I'm exploring a free tool to help others build theirs. Patients, carers, doctors and nurses: tell me what you'd want on it.

Get in touch → See the sheet

Russ Read-Barrow's One View card, correct as at 3 November 2026. The same information is set out as text on this page.

PDF Open One View Plain text (.txt) JSON One View JSON

The sheet

One sheet. Diagnosis, genetics, the chemo I'm on and the exact doses, my latest bloods, how my tumour marker has moved, what the scans say, what I'm taking, and what I'm looking for.

Doctors, nurses, second opinions

Download the PDF, or copy the plain-text version straight into an email or a clinic note. No login, no forms, no chasing me for letters.

Researchers and AI agents

FC:AI One View is the short, structured summary, built on the HL7 mCODE structure: oneview.json. The complete feed — every blood panel, the chemo log, the sequencing manifest — is profile.json, with the source PDFs in the full record.

Everyone else

This is what's possible with the information you already have about yourself. Why I'm doing it →

Right now

The five things that change

Everything below is checked against the source documents before it goes up. Nothing is estimated or carried forward. If a number isn't in a report, it isn't here.

Chemo, doses & plan

C6 done · maintenance from C7

From C7 (~12 Nov): 5-FU/folinic acid + cetuximab, as maintenance. Irinotecan is dropped. Agreed at the results call on 2 November 2026; clinic letter to follow.

Up to C6 it was FOLFIRI + cetuximab (rechallenge, 3rd block), every 14 days — my third block of this combination and my 17th cycle of it since April 2025.

C119 Aug 26

C22 Sep 26

C316 Sep 26

C430 Sep 26

C514 Oct 26

C629 Oct 26

C7~12 Nov 26

Cetuximab	500 mg/m²	1000 mg
Irinotecan	180 mg/m²	400 mg stopping at C7
5-FU bolus	400 mg/m²	900 mg
5-FU infusion (46h)	2400 mg/m²	5000 mg
Folinic acid		350 mg

Doses as given to C6: full doses, dose-banded · BSA 2.08 m² (84.5 kg, 185 cm, 16 Sep 26). From the prescription chart for cycle 4. From C7 the irinotecan comes out and the rest continues.

Restaging CT 28 Oct: partial response. Plan agreed at the results call on 2 Nov 2026 (clinic letter to follow): irinotecan is dropped from C7 (~12 Nov) and 5-FU/folinic acid + cetuximab continues as maintenance, for disease and symptom control.

C6 given 29 Oct 2026 · CT 28 Oct: partial response · next cycle ~12 Nov, maintenance

Pharmacogenetics

Exacta · 1 Sep 2025

How my genes handle the drugs I'm given. Same report as the tumour genetics, and arguably the most directly useful thing in it.

Gene	Result	What it means
UGT1A1	28/28 POOR METABOLISER	Slower irinotecan clearance, so a higher risk of neutropenia and diarrhoea. The report advises considering a reduced dose with close monitoring. Also the genetic cause of my Gilbert's syndrome.
DPYD	1/1	Normal metaboliser. Standard 5-FU and capecitabine dosing. This is the test that catches people at risk of severe 5-FU toxicity; mine is normal.
ERCC1, XPC	variants	Associated with a higher risk of toxicity from platinum drugs such as oxaliplatin.

Lab cell-kill test

An in-vitro assay on my circulating tumour cells, measuring how much each drug killed in a dish: 5-FU 65%, oxaliplatin 50%, trifluridine 39%, irinotecan 37%. The same liquid biopsy found 1 circulating tumour cell per ml, with tumour cellularity of 25% in the resection block.

A dish is not a person. This is not evidence that any of these drugs will work for me, and it is not a ranking. I publish it because it is part of my record, and because researchers keep asking whether I have had functional testing.

Bloods

28 October 2026

CEA (my tumour marker) was 46.5 ug/L on 28 October 2026, against 44.6 on 29 September and 47.3 on 12 October. Normal is roughly under 5. That is down 68% from the 1 September peak of 146, and steady since late September — flat rather than falling or rising. ALP has come down for the first time in months: 102 (July) → 165 → 179 → 169 → 149 now. Haemoglobin is up to 134 and back inside range, bilirubin is 9, and platelets, white cells and neutrophils are all normal. Red cells remain marginally low at 4.31. The restaging CT on 28 October showed a partial response in the lung metastases and chest nodes, with the liver stable — so the marker was flat while the scan improved. At the results call on 2 November my oncologist and I agreed to drop the irinotecan and move to 5-FU/folinic acid + cetuximab as maintenance from C7, around 12 November.

Marker	Result	Range
Haemoglobin	134 g/L	130–170
Red cells	4.31 ×10¹²/LLOW	4.40–5.80
White cells	6.46 ×10⁹/L	3.0–10.0
Neutrophils	3.28 ×10⁹/L	2.0–7.5
Lymphocytes	2.17 ×10⁹/L	1.2–3.65
Platelets	288 ×10⁹/L	150–400
ALT	33 U/L	10–50
AST	27 U/L	10–50
ALP	149 U/LHIGH	30–130
GGT	30 U/L	10–71
Bilirubin	9 µmol/L	0–20
Albumin	41 g/L	35–50
Creatinine	69 µmol/L	59–104
eGFR	>90 mL/min/1.73m²
Sodium	137 mmol/L	133–146
Potassium	3.8 mmol/L	3.5–5.3
Magnesium	0.85 mmol/L	0.7–1.0

Every draw since April 2025Full bloods table →

Clinic letters

24 Aug 2026

24 Aug 2026 · Consultant clinical oncologist · Pre-assessment before cycles 2 and 3

First cycle done, with the expected side effects, mainly fatigue.
Go ahead with the next two cycles, pending blood results.
CEA to be monitored. Repeat scan after five cycles to weigh response against side effects and quality of life.
Next review: telephone consultation before cycles 4 and 5. WHO performance status 0.

4 Aug 2026 · Consultant clinical oncologist · Review of expedited CT

CT shows progression at the previous lung and chest lymph node sites, a new liver metastasis (segment 7) and some new small-volume lung metastases. This explains the persistent cough.
Plan: restart FOLFIRI + cetuximab. If it responds well, step down after 8–12 weeks to maintenance 5-FU + cetuximab rather than a full treatment break.
Mistletoe injections to be suspended during chemo, and most supplements too. Any I want to keep can be checked by pharmacy for interactions.

Summaries of the clinical content, not the letters themselves. Personal details and anything that isn't about the cancer are left out.

Scans

28 Oct 2026

28 Oct 2026 · CT chest, abdomen & pelvis

Partial response in the lung metastases and chest nodes; liver stable

Compared with July 2026. Multiple hilar and parenchymal lung nodules have partially reduced and a right upper lobe nodule has cavitated. Mediastinal nodes are smaller, including the subcarinal and left AP window nodes. Atelectasis unchanged, no pleural effusion. The segment VII liver low density is potentially minimally reduced, overall stable. No peritoneal disease, ascites or abdominopelvic lymphadenopathy. Skeleton unchanged. The radiologist’s comment: “Partial response of the intrathoracic lymph nodes and lung metastases. Stable appearances of the liver.”

23 Jul 2026 · CT chest, abdomen & pelvis

Progression above and below the diaphragm; new segment VII liver metastasis

Compared with May 2026: left perihilar soft tissue up from 3.9 cm to 6.0 cm with distal atelectasis; right lower lobe up from 3.3 cm to 4.2 cm; additional pulmonary nodules new or enlarging; mediastinal nodes increased, particularly subcarinal; new low-density lesion in hepatic segment VII, considered recurrent disease. Portal vein patent. No peritoneal disease, ascites, abdominopelvic adenopathy or aggressive bone lesion.

19 Jun 2026 · CT head with contrast

Normal

No lesions and no leptomeningeal enhancement.

12 May 2026 · CT chest, abdomen & pelvis

Good response in the mediastinum and lungs

“Good response to treatment within the mediastinum and lungs.” Compared with January 2026. End of the Feb–May 2026 block.

6 Jan 2026 · CT thorax, abdomen & pelvis

Further mild progression

“Further mild increase in intrathoracic lymph nodes and pulmonary disease. Short very severe stenosis left upper lobe bronchus suggesting imminent occlusion.”

Plan agreed 2 Nov: maintenance from C7 (~12 Nov)All scans →

Protocol & a day on chemo

3 November 2026

Most of my integrative protocol (off-label drugs, supplements, mistletoe) is paused while I'm on chemo, on my oncologist's advice. This is everything I'm actually taking.

Chemo day	Standard pre-meds (Akynzeo, dexamethasone, chlorphenamine, atropine) · pegfilgrastim 24h after
Supportive	Dexamethasone ×3 days · domperidone · loperamide · doxycycline + Plazon (skin) · Laxido · antihistamine · zopiclone PRN
Other	Citalopram 30 mg (breakfast) · melatonin 60 mg (evening) · metformin MR 500 mg twice daily (from cycle 5 day 7) · loratadine 10 mg
Paused	Mistletoe and most supplements / off-label drugs, during chemo on my oncologist's advice

The previous protocol (June 2026) is kept in the full record.

A typical day in the first week of a cycle

08:00Domperidone (anti-sickness)
08:30Breakfast with citalopram, antihistamine and coffee
09:00Home-made tomato juice and raw apple cider vinegar mix (mostly because I crave it)
09:30Laxido, dose 1 of 2
Late morningDoxycycline (prescribed for cetuximab skin rash)
12:30–15:00Bed rest / sleep
Day 4 onwardsMetformin MR 500 mg twice daily, from cycle 5 day 7
15:30Laxido, dose 2 of 2
18:00Family dinner
BedtimeMelatonin 60 mg · zopiclone if needed during the post-steroid wide-awake nights

How I got here

Treatment history

Dec 21–Feb 22Neoadjuvant XELOX ×4 · good partial response
Mar–Oct 22Primary resected · liver met resected (R0) · adjuvant CAPOX
Oct 22–Apr 23Lung mets appear, progress · SABR 55 Gy/5
Jun & Aug 24Lung ablations (1 left, then 1 left + 4 right)
Feb 25EBUS confirms mediastinal nodal disease
Apr–Jul 25FOLFIRI + cetuximab ×6 · good partial response
Feb–May 26Rechallenge ×6 · good response (CT 12 May)
Jul–Aug 26Progression during the break · FOLFIRI + cetuximab restarted 19 Aug

Genetics

Molecular profile

KRAS/NRAS wild-typeBRAF wild-typepMMR / MSSHER2 IHC 0TMB-low · 3 Mut/MbPD-L1 <1% (22C3, 28-8)

APC p.S1415Rfs*4	Frameshift · tissue MAF 8.5% · cfDNA 0.62%
TP53 p.R342*	Nonsense · tissue MAF 9.21%

VUS: RUNX1T1, FANCM, CIC, BCR, CYP2D6. Exploratory (Astron/ICC): MTOR and VEGFR1/2 protein positivity, HMGB1 overexpression. Source: EXACTA report, 1 Sep 2025. Smouldering myeloma under haematology surveillance. Last myeloma markers in my records: 30 Jun 2025, IgG kappa paraprotein, free kappa light chains 22.8 mg/L (range 3.3–19.4).

The ask

Is there anything else I should be doing?

If you understand this profile (a patient with something similar, an oncologist, a scientist, a geneticist) I want to hear from you. Trials, combinations, tests, people I should be talking to.

If it's a juice, a book, or something that worked for a friend's uncle: I know it comes from a good place, but I've had my fill.

How to get in touch What's missing from my record

⚕️ This is my data, shared openly. It is not medical advice and it is not a plan to copy. Take anything useful to your own clinical team.